SCHEDULE: Millennium Entities Reduce Spruce Biosciences Stake

Integrated Core Strategies, Millennium Management, and Israel A. Englander report a reduction in their beneficial ownership of Spruce Biosciences, Inc. common stock to below 5%.

Summary

• This filing is a Schedule 13G, an amendment indicating a change in beneficial ownership of Spruce Biosciences, Inc. common stock.
• Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander are the reporting persons.
• As of June 30, 2026, these entities have ceased to beneficially own more than 5% of the class of securities.
• The aggregate amount beneficially owned by each reporting person is 160,981 shares, representing 5.8% of the class.
• The filing confirms a joint filing agreement among the reporting persons for this Schedule 13G.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the reporting persons ceasing to beneficially own more than 5 percent of the class of securities, indicating a divestment or reduction in stake.

Negatives

• The reporting persons have ceased to beneficially own more than 5 percent of the class of securities of Spruce Biosciences, Inc.
• This indicates a reduction in their investment or control over the company's shares.

Risks

• Potential for further reduction in ownership by these significant entities, which could impact share price.
• The reduction in stake might signal a lack of confidence in the company's future performance from these institutional investors.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports a change in beneficial ownership.

Industry Context

StockSavvy.ai notes that a Schedule 13G filing typically indicates passive investment. However, the reduction in ownership below the 5% threshold by significant institutional investors like Millennium Management can be interpreted as a signal of reduced conviction or a strategic shift in their portfolio.

Stakeholder Impact

• Shareholders may react to the reduced stake by significant investors, potentially leading to short-term price volatility.
• The market may interpret this as a signal regarding the company's future prospects, influencing investor sentiment.

Next Steps

• Monitor future filings from these reporting persons for any further changes in their stake in Spruce Biosciences, Inc.

Key Dates

Recommendation

The filing indicates a reduction in ownership by significant institutional investors, which is a negative signal. However, it does not provide new operational or financial data about the company itself. Therefore, a 'hold' recommendation is appropriate, suggesting investors await further information or observe market reaction before making a decisive move.

Keywords

Spruce Biosciences, Schedule 13G, Beneficial Ownership, Millennium Management, Integrated Core Strategies, Shareholder, Investment